An evaluation of pitavastatin for the treatment of hypercholesterolemia

References

• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38:2459–2472.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39:2526–2539.
   Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. 2010;375:735–742.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658–1669.
   PubMed Web of Science ®Google Scholar
• Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92:112–117.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112:71–105.
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–125.
   PubMed Web of Science ®Google Scholar
• Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.
   PubMed Web of Science ®Google Scholar
• Catapano AL. Pitavastatin - pharmacological profile from early phase studies. Atheroscler Suppl. 2010;11:3–7.
   PubMed Web of Science ®Google Scholar
• Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung. 1997;47:904–909.
   PubMed Web of Science ®Google Scholar
• Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7:138–144.
   PubMedGoogle Scholar
• Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004;324:835–839.
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung. 2002;52:251–255.
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162:373–379.
   PubMed Web of Science ®Google Scholar
• Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. 2002;71:2403–2412.
   PubMed Web of Science ®Google Scholar
• Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am J Cardiol. 2000;85:178–183.
   PubMed Web of Science ®Google Scholar
• Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:157–164.
   PubMed Web of Science ®Google Scholar
• Park S, Kang HJ, Rim SJ, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther. 2005;27:1074–1082.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb. 2009;16:654–661.
   PubMed Web of Science ®Google Scholar
• Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59:239–252.
   PubMed Web of Science ®Google Scholar
• Kowa Pharmaceuticals America, Inc. Livalo (pitavastatin) package insert (Version 9.1 of November 2016). Montgomery, AL 36117, USA.
   Google Scholar
• Fujino H, Nakai D, Nakagomi R, et al. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung. 2004;54:382–388.
   PubMed Web of Science ®Google Scholar
• Yamada I, Fujino H, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica. 2003;33:789–803.
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Tsunenari Y, et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004;34:961–971.
   PubMed Web of Science ®Google Scholar
• Morgan RE, Campbell SE, Yu CY, et al. Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012;60:42–48.
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung BM, Lau GK. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol. 2005;59:291–297.
   PubMed Web of Science ®Google Scholar
• Warrington S, Nagakawa S, Hounslow N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. Clin Drug Investig. 2011;31:735–743.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139–146.
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Ogawa S, et al. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005;57:1305–1311.
   PubMed Web of Science ®Google Scholar
• Choi MK, Shin HJ, Choi YL, et al. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011;41:24–34.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Matsushima S, et al. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005;68:800–807.
   PubMed Web of Science ®Google Scholar
• Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag. 2009;5:921–936.
   PubMedGoogle Scholar
• Ose L. Pitavastatin: finding its place in therapy. Ther Adv Chronic Dis. 2011;2:101–117.
   PubMedGoogle Scholar
• Morikawa S, Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC Human umbilical vein endothelial cells. J Atheroscler Thromb. 2002;9:178–183.
   PubMedGoogle Scholar
• Hiraoka M, Nitta N, Nagai M, et al. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Sci. 2004;75:1333–1341.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kobayashi H, Sato F, et al. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb. 2003;10:109–116.
   PubMedGoogle Scholar
• Ohbayashi H, Miyazawa C, Miyamoto K, et al. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb. 2009;16:490–500.
   PubMed Web of Science ®Google Scholar
• Morikawa S, Takabe W, Mataki C, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb. 2004;11:62–72.
   PubMedGoogle Scholar
• Betteridge J. Pitavastatin - results from phase III & IV. Atheroscler Suppl. 2010;11:8–14.
   PubMed Web of Science ®Google Scholar
• Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidology. 2009;4:291–302.
   Web of Science ®Google Scholar
• Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25:2755–2764.
   PubMed Web of Science ®Google Scholar
• Stender S, Budinski D, Gosho M, et al. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013;20:40–53.
   PubMed Web of Science ®Google Scholar
• Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013;20:29–39.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther. 2011;28:811–823.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther. 2011;28:799–810.
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M, Kastelein JJP, Hovingh GK, et al. Efficacy and safety of pitavastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe. J Atheroscler Thromb. 2018;25:422–429.
   PubMed Web of Science ®Google Scholar
• Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201:345–352.
   PubMed Web of Science ®Google Scholar
• Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30:1089–1101.
   PubMed Web of Science ®Google Scholar
• Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb. 2008;15:345–350.
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Douzono T, Kawakita K, et al. A Large−scale, Long−term, Prospective Post−marketing Surveillance of Pitavastatin (LIVALO Tablet). Jpn Pharmacol Ther. 2008;36:709–731.
   Google Scholar
• Teramoto T, Shimano H, Yokote K, et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11:817–828.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Takahashi T, Yamada H, et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (pitavastatin evaluation of atherosclerosis regression by intensive cholesterol-lowering therapy) study. Eur J Prev Cardiol. 2013;20:1069–1079.
   PubMed Web of Science ®Google Scholar
• Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54:293–302.
   PubMed Web of Science ®Google Scholar
• Hiro T, Kimura T, Morimoto T, et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome – serial intravascular ultrasound observations from the Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome trial (the JAPAN-ACS trial). Circ J. 2010;74;1165–1174.
   Web of Science ®Google Scholar
• Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): A randomized superiority trial. Circulation. 2018;137:1997–2009.
   PubMed Web of Science ®Google Scholar
• Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210:202–208.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–2564.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385:351–361.
   PubMed Web of Science ®Google Scholar
• Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13:1047–1055.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Orsoni A, Robillard P, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin. 2014;30:775–784.
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15:269–275.
   PubMedGoogle Scholar
• Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241:409–418.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Kishimoto J, Ito C, et al. Japan prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetology International. 2011;2:134–140.
   Google Scholar
• Fujino H, Saito T, Tsunenari Y, et al. Interaction between several medicines and statins. Arzneimittelforschung. 2003;53:145–153.
   PubMed Web of Science ®Google Scholar
• Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Curr Med Res Opin. 2011;27::1551–1562.
   PubMed Web of Science ®Google Scholar
• Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999;48:543–552.
   PubMed Web of Science ®Google Scholar
• Rebello S, Zhao S, Hariry S, et al. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. Eur J Clin Pharmacology. 2012;68:697–708.
   PubMed Web of Science ®Google Scholar
• Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60:494–497.
   PubMed Web of Science ®Google Scholar
• Hu M, Mak VW, Yin OQ, et al. Effects of grapefruit juice and slco1b1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet. 2013;28:104–108.
   PubMed Web of Science ®Google Scholar
• Morgan RE, Campbell SE, Suehira K, et al. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 2012;60:158–164.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301:1042–1051.
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Tsunenari Y, et al. Effect of gemfibrozil on the metabolism of pitavastatin–determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Inter. 2004;20:25–42.
   PubMedGoogle Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010;11:323–332.
   PubMed Web of Science ®Google Scholar
• Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol. 2014;10:51–65.
   PubMed Web of Science ®Google Scholar
• Hasunuma T, Nakamura M, Yachi T, et al. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Medicines. 2003;19:381–389.
   Google Scholar
• Inagaki Y, Hunt T, Arana B, et al. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol. 2011;51:1302–1309.
   PubMed Web of Science ®Google Scholar
• Yu CY, Campbell SE, Zhu B, et al. Effect of pitavastatin vs rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr Med Res Opin. 2012;28:187–194.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang W, Huang WH, et al. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:1933–1938.
   PubMed Web of Science ®Google Scholar
• Jung JA, Noh YH, Jin S, et al. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Clin Ther. 2012;34:958–965.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Sponseller CA, Ward DJ, et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4:e284–e94.
   PubMed Web of Science ®Google Scholar
• Algharably EA, Filler I, Rosenfeld S, et al. Statin intolerance - a question of definition. Expert Opin Drug Saf. 2017;16:55–63.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8:S58–71.
   PubMed Web of Science ®Google Scholar
• Kurogi K, Sugiyama S, Sakamoto K, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study. J Cardiology. 2013;62:87–94.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shoda T, Yanai H, et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis. 2013;226:161–164.
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Pitavastatin: novel effects on lipid parameters. Atheroscler Supplements. 2011;12:277–284.
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310.
   PubMed Web of Science ®Google Scholar
• Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:484–525.
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–135.
   PubMed Web of Science ®Google Scholar
• Miyamoto-Sasaki M, Yasuda T, Monguchi T, et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb. 2013;20:708–716.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2013;2014(129):S1–45.
   Google Scholar
• Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017;24:19–25.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Yokote K, Saito Y, et al. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007;8:2315–2327.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Chan P, Liu ZM. Statin responses in Chinese patients. J Atheroscler Thromb. 2018;25:199–202.
   PubMed Web of Science ®Google Scholar
• Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38:2264–2276.
   PubMed Web of Science ®Google Scholar